3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
120
Carcinoma, Hepatocellular
69
Ovarian Neoplasms
64
Neoplasms
36
Carcinoma, Non-Small-Cell Lung
35
Fallopian Tube Neoplasms
29
Brain Neoplasms
24
Glioblastoma
23
Colonic Neoplasms
21
Breast Neoplasms
19
Endometrial Neoplasms
18
Neoplasm Metastasis
17
Uterine Cervical Neoplasms
15
Stomach Neoplasms
15
Rectal Neoplasms
15
Lung Neoplasms
14
Liver Neoplasms
11
Triple Negative Breast Neoplasms
10
Melanoma
8
Glioma
8
Carcinoma, Renal Cell
8
Carcinoma, Ovarian Epithelial
8
Biliary Tract Neoplasms
8
Recurrence
7
Colorectal Cancer Metastatic
7
Squamous Cell Carcinoma of Head and Neck
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Advanced Solid Tumors
6
Small Cell Lung Carcinoma
5
Pancreatic Neoplasms
5
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dihydropyrimidine Dehydrogenase Deficiency
×
Bevacizumab
×
1 year
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled